About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Phase I Nicotinic Agonist Treatment Trial for Autism

Phase I Nicotinic Agonist Treatment Trial for Autism

NCT02111551·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

University of Colorado, Denver

Age

18–50

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

age 18-50
meet DSM-5 criteria for Autism Spectrum Disorder, Levels 1 or 2, as defined by Autism Diagnostic Observation Schedule
non-smoking persons
in good health

You may not be if

persons with estimated verbal and nonverbal IQ \< 70.
abuse of other substances.
Persons not sufficiently fluent in English to permit testing
those with history of severe head injury
Fragile X Syndrome
Rett Syndrome

The record

StatusTerminated

PhasePhase 1

Taking part2

StartedJun 2015

UpdatedJun 16, 2016

Conditions

Where1

University of Colorado Denver
Aurora, Colorado, United States